Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Incidence of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), infections and cardiovascular events across different chimeric antigen receptor (CAR) T-cell therapy products in large B-cell lymphoma (DLBCL): A nationwide analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

HMHimil MahadeviaKMKarnav ModiRSRaj Shah

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals differences in cytokine release syndrome and infections among CAR T-cell therapies for DLBCL, indicating clinical implications.

Key Points

  • Kymriah showed lower CRS rates compared to Yescarta, while Breyanzi demonstrated lower ICANS rates.
  • Infections were similar across CAR T therapies, with no significant differences in complications like pneumonia and sepsis.
  • The study utilized data from the National Inpatient Sample, employing ICD-10 codes to identify adverse events and outcomes.
  • Monitoring for adverse cardiac events remains crucial across all CAR T-cell products, highlighting potential risks.

Cite This Study

Mahadevia et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc3ehttps://doi.org/10.1182/blood-2025-8012
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comparative CRS risk across CAR-T constructs in DLBCL in real-world cohorts2025 · 1 citations
  2. 2Beyond the trial: Real-world CRS, icans, and healthcare burden of CAR T-cell therapy across US oncology practices2025 · 1 citations
  3. 3A post-marketing pharmacovigilance analysis of cardiotoxicities following chimeric antigen receptor T-cell therapy using the FDA adverse event reporting system2025
  4. 4Cardiovascular adverse events after CAR-T, BiTEs and TILs therapies: a systematic review and meta-analysis2025
  5. 5Burden and outcomes of CAR T-cell therapy toxicities in DLBCL, multiple myeloma, and B-ALL: A nationwide analysis2025